
Last updated: 2026-09-21 20:59:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Filana Therapeutics, Inc. (FLNA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.74, with a market capitalization of $35.07M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.67 to $2.27. This page covers its latest market performance, valuation, price trends and company information.
$35.07M | |
$0.74 | |
$2.27 | |
$0.67 | |
$0.73 | |
320.61K | |
314.84K | |
-- | |
$2.27 | |
$0.67 | |
-- | |
-- |
Filana Therapeutics, Inc. (FLNA) is trading at $0.74 in after-hours trading as of 2026-09-21 20:44:00, up 2.07% ($0.02) from the regular-session close of $0.73.
After-hours trading shows how investors are pricing FLNA after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Filana Therapeutics, Inc. (FLNA) moved from $0.81 to $0.74, representing a decline of 8.52% ($0.07).
The stock traded between $0.67 and $0.81 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 317.66 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 4.4%
FLNA is currently trading at $0.74, placing it 4.4% of the way from its 52-week low of $0.67 to its 52-week high of $2.27. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 20 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Filana Therapeutics, Inc. (FLNA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.